Skip to main content
Clinical Trials/NL-OMON52323
NL-OMON52323
Completed
Phase 4

A Prospective, Randomized, Multi-center Study to Assess the SaFety of the Orsiro Mission Stent compared to the ResoLute Onyx Stent in Subjects at High Risk for Bleeding in combination With 1-month Dual Antiplatelet Therapy (DAPT). - BIOFLOW-DAPT study

BIOTRONIK AG0 sites1 target enrollmentTBD

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Not specified
Sponsor
BIOTRONIK AG
Enrollment
1
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

Trial is onging in other countries

Registry
who.int
Start Date
TBD
End Date
September 12, 2022
Last Updated
2 years ago
Study Type
Interventional

Investigators

Eligibility Criteria

Inclusion Criteria

  • \- An acceptable candidate for treatment with a Drug Eluting Stent (DES)
  • \- Considered at high bleeding risk
  • \- \>\= 18 years old

Exclusion Criteria

  • \- previously experienced stent or scaffold thrombosis in any coronary vessel.
  • \- Revascularization of any target vessel within 9 months prior to the index
  • procedure or previous PCI of any non\-target vessel within 72 hours prior to or
  • during the index procedure.
  • \- judged by physician as inappropriate for discontinuation from DAPT at 1 month
  • following index procedure, due to another condition requiring chronic DAPT.

Outcomes

Primary Outcomes

Not specified

Similar Trials